-
10010233-1An inhibitor of Akt1 translocation that also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) (IC50 = 79 µM).
-
10010233-100An inhibitor of Akt1 translocation that also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) (IC50 = 79 µM).
-
10010233-250An inhibitor of Akt1 translocation that also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) (IC50 = 79 µM).
-
10010233-500An inhibitor of Akt1 translocation that also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) (IC50 = 79 µM).
-
10012565-10A physically smaller, less hydrophobic version of the lidocaine derivative QX314 designed to be more permeable to the TRPV1 ion channel for selective analgesia through TRPV1.
-
10012565-100A physically smaller, less hydrophobic version of the lidocaine derivative QX314 designed to be more permeable to the TRPV1 ion channel for selective analgesia through TRPV1.
-
10012565-25A physically smaller, less hydrophobic version of the lidocaine derivative QX314 designed to be more permeable to the TRPV1 ion channel for selective analgesia through TRPV1.
-
10012565-50A physically smaller, less hydrophobic version of the lidocaine derivative QX314 designed to be more permeable to the TRPV1 ion channel for selective analgesia through TRPV1.
-
10010032-1A reversible inhibitor of FAAH activity exhibiting an IC50 value of 1.3 µM.
-
10010032-10A reversible inhibitor of FAAH activity exhibiting an IC50 value of 1.3 µM.
-
10010032-5A reversible inhibitor of FAAH activity exhibiting an IC50 value of 1.3 µM.
-
10010032-500A reversible inhibitor of FAAH activity exhibiting an IC50 value of 1.3 µM.